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A total of 50% of patients undergoing IVF treatment has previously been estimated
to fulfill the POSEIDON classification criteria; importantly, although the reproductive
prognosis differs between patients, POSEIDON patients share the same characteristic
of a low ovarian response to exogenous gonadotropin stimulation—independent of age.
POSEIDON patients require focused attention as regards ovarian stimulation in order to
increase the chances of having at least one euploid blastocyst for transfer—the success
criterion for stimulation set forth by the POSEIDON Group. The key to success seems
to be individualization in all steps of treatment. In this perspective article we discuss
the future impact of the POSEIDON stratification for daily clinical practice as well as
for research.
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FUTURE PERSPECTIVES OF POSEIDON STRATIFICATION FOR
DAILY CLINICAL PRACTICE
As previously mentioned in this supplement, the incitement to propose the POSEIDON criteria
was the high degree of heterogeneity seen in the ESHRE Bologna criteria population (1, 2). With
the new POSEIDON stratification significantly more homogenous sub-populations were created,
taking age, ovarian reserve, and previous ovarian responses after stimulation with gonadotropins
into account. Thus, the overall idea of the POSEIDON stratification was to not only guide clinicians
regarding clinical management of the patient, but also to be a counseling tool to help set patient
expectations prior to initiation of ovarian stimulation. For this purpose, a number of clinical
recommendations in terms of type of GnRH analog, gonadotropin type and dosing were suggested
in order to obtain the new marker of success: the number of oocytes needed in each individual
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patient to obtain one euploid blastocyst. This quite naturally led
to the subsequent development of the ART calculator (3). As seen
from Figures 1, 2 the main factor distinguishing Groups 1 and
2 from Groups 3 and 4 is the ovarian reserve and a previous
response to stimulation with exogenous gonadotropins (1, 2, 5).
Until now clinical management of the low prognosis patient
has primarily been based on small studies including heterogenous
populations which left clinicians with poor evidence to
manage the low prognosis patient—and often a “trial and
error” strategy was adopted by individual clinicians. With
the POSEIDON stratification the clinician will very quickly
get an impression of whether the individual patient fulfills
the criteria of being a POSEIDON patient—and if positive
(∼50%)—to which of the four groups the patient belongs
(6). This places POSEIDON as a daily partner in the clinic;
moreover, the POSEIDON patient generally is a patient who
needs more clinical consideration and individualization when
compared to the other half of patients, constituted by non-
POSEIDON patients.
As mentioned previously, patients in POSEIDON groups
1 and 2 underwent one or more stimulations leading to an
unexpected impaired ovarian response. Either a low response
resulting in <4 oocytes (Groups 1a and 2a) or a suboptimal
response, resulting in 4–9 oocytes (Groups 1b and 2b). As seen
from Figure 1 it is suggested that POSEIDON groups 1 and
2 patients undergo their next stimulation with an increase in
rFSH dosing, rLH supplementation from day 1 of stimulation
as well as GnRH antagonist co-treatment. The main difference
between groups 1 and 2, is age and consequently, a difference
in oocyte euploidy, and thus, reproductive potential. In general,
one could classify the Group 1 patient as a patient with a
good ovarian reserve—and due to her age also an expected
good oocyte quality (7). In contrast, the Group 2 patient
has an age-related increased oocyte aneuploidy although the
ovarian reserve is good (7). This means that the number of
oocytes needed to obtain success is significantly higher for
the aging patient, but with her good ovarian reserve she
is likely to reach the estimated number of oocytes needed
for one euploid blastocyst (3). This means that future use
of the POSEIDON stratification with or without the use of
the ART calculator will help clinical decision-making as well
as counseling.
Groups 3 and 4 are characterized by a low ovarian
reserve which per se induces a poor reproductive prognosis.
However, age makes a significant difference for success, and
it is expected that the younger patient will have a four-
times higher probability of a live birth per transfer as
compared to the older patient– 20 vs. 5% (8). Again, the
POSEIDON stratification will help clinical decision-making
and counseling. As shown in Figure 2, the suggested handling
of the POSEIDON group 3 patient would include either a
long GnRHa down-regulation or a “primed” GnRH antagonist
co-treatment (synchronization with short term estradiol or
progestin treatment or oral contraceptive pill treatment) followed
by stimulation with a maximum dose of 300 rFSH. In
selected cases with a low oocyte yield and based on the
estimate made by the ART calculator, DUO-Stim should be
recommended for oocyte or embryo accumulation to shorten
time to pregnancy (9–11).
With the increasing delay in child bearing, POSEIDON
group 4 patients become more and more prevalent—in some
centers constituting 55% of the POSEIDON population
(6).The dual negative effect of a reduced ovarian reserve
(quantity) as well as an age related increase in aneuploidy
(quality) makes this category of patients difficult to handle
(7). The POSEIDON recommendation for this patient would
include either long GnRHa down-regulation or a “primed”
GnRH antagonist co-treatment, followed by stimulation
with a maximum dose of 300 rFSH and 150 IU rLH from
day one of stimulation. In selected cases with low oocyte
yield, DUO-Stim should be recommended for oocyte or
embryo accumulation bearing in mind cost-efficiency—
especially in women >40 years old (9–11). Although the
initial attitude toward oocyte donation could be negative in
a large proportion of older Group 4 patients (12), from a
scientific point of view the best chance for a live birth would be
oocyte donation.
Taken together, we see the POSEIDON
stratification as a daily tool in future clinical
practice, supporting not only clinical, but also patient
decision-making.
FUTURE PERSPECTIVES OF POSEIDON
STRATIFICATION FOR RESEARCH
Currently, retrospective analyses of large databases may match
patients so as to fit into one of the four POSEIDON
groups. However, it is quite unlikely that patients were
treated according to the recommendations made by the
POSEIDON stratification. Thus, future RCT’s are necessary
to evaluate the stratification and the recommendations set
forth in this supplement. In this aspect, POSEIDON groups
1 and 2 need to be studied separately from groups 3
and 4.
Future Research in Groups 1 and 2
Groups 1 and 2 encompass good reserve patients, some of
whom have the presence of FSH-R and LH-R polymorphisms
or variant LHβ (13). Previous reports show that an increase
in rFSH in patients with an unexpected low response to
ovarian stimulation in the first stimulation cycle increases
the number of oocytes retrieved which could be the effect
of FSH receptor polymorphisms (14, 15). As regards rLH
supplementation this has previously been proven to significantly
increase clinical pregnancy rates (16–19). Future studies should
evaluate the benefit of screening patients prior to their future
stimulation for FSH-R and LH-R polymorphisms as well as
variant LHβ (20). From the findings, the subsequent stimulation
should be tailored accordingly; thus, patients with FSH-R
polymorphisms should have an increase in FSH dosing, whereas
patients with LH-R polymorphisms and presence of variant
LHβ should be treated with rLH from day 1 of stimulation.
The primary end point of these studies should be cumulative
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FIGURE 1 | Best practice in POSEIDON groups 1 and 2. (A) POSEIDON recommends use of GnRH antagonist co-treatment for all patients in POSEIDON groups 1
or 2. (B) Ovarian stimulation strategy: First choice should be an increase in daily rFSH dose by 75–150 IU. In POSEIDON Group 1 patients with follicular stagnation at
follicle sizes 1–12mm, rLH 75–150 IU daily should be added from day 1 of stimulation. In POSEIDON 2 patients rLH 75–150 IU daily should be added to all patients
from day 1 of stimulation. (C) Ovulation trigger strategy: GnRHa is mandatory in the follicular phase stimulation of the DuoStim protocol. All trigger agents can be used
in the luteal phase stimulation. In non DuoStim GnRH antagonist cycles, the choice of trigger between GnRHa and hCG should rely on the embryo transfer strategy
(fresh or frozen), patient characteristics (e.g., hypo-hypo) and clinical experience. In cases with a low FOI (4), clinicians should consider pretreatment including short
term estrogen or progestin therapy, or OCP for synchronization of the follicles prior to stimulation, adjuvant LH activity during stimulation, or changing trigger strategy
to either dual or double trigger. In case of an insufficient number of oocytes retrieved as determined by the ART calculator, the probability of transferring a euploid
embryo should be discussed with the patient to counsel whether an immediate transfer or a new stimulation should be suggested (3).
live birth (CLBR), i.e., the live births obtained after one
embryo transfer and the subsequent frozen cycles within a
2–3-years period. The suggested secondary endpoint is the
achievement of the number of mature oocytes needed to obtain
at least one euploid blastocyst as per the ART calculator
estimation (3).
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FIGURE 2 | Best practice in POSEIDON groups 3 and 4. (A) Pretreatment is rarely the first option in low prognosis patients, but in case of low response to ovarian
stimulation, e.g., asynchrony of follicular growth and inadequate ovarian response, pretreatment should be considered. The choice should rely on availability, clinical
experience and patient preference. Stimulation protocol might start using GnRH antagonist co-treatment keeping in mind the possibility of converting to DuoStim to
achieve the individualized oocyte number (according to the ART calculator). Otherwise a long GnRHa protocol should be considered first choice. (B) Ovarian
stimulation strategy: First choice in Poseidon group 3 is the GnRH antagonist cycle using either 300 IU daily of rFSH alone or Corifollitropin alfa followed by either rFSH
or hMG. In POSEIDON group 4 patients, rLH (75–150 IU daily) should be added from day 1 of stimulation, unless the combination of Corifollitropin alfa and hMG was
chosen. GnRH antagonist co-treatment allows the use of Duostim. (C) Ovulation trigger strategy: In the long GnRHa down-regulation protocol hCG is mandatory as
ovulation trigger, whereas GnRHa is mandatory in the follicular phase stimulation of the DuoStim protocol. All trigger agents can be used for the luteal phase
stimulation. In non DuoStim GnRH antagonist cycles, the choice of trigger between GnRHa and hCG should rely on the embryo transfer strategy (fresh or frozen),
patient characteristics, and clinical experience. In cases with a low antral follicle to oocyte ratio (FOI) as determined on trigger day (4), clinicians should consider:
pretreatment including short term estrogen or progestin therapy, or OCP for synchronization of the follicles prior to stimulation, adjuvant LH activity during stimulation,
or changing trigger strategy to either dual or double trigger. In case of an insufficient number of oocytes retrieved as determined by the ART calculator, the probability
of transferring a euploid embryo should be discussed with the patient to counsel whether an immediate transfer or a new stimulation should be suggested (3).
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Future Research in Groups 3 and 4
The question asked for groups 3 and 4 is—can we increase the
number of growing follicles and subsequently the number of
competent oocytes? First of all, which GnRH analog regimen is
the most optimal for Groups 3 and 4: the long GnRHa down-
regulation protocol—or the GnRH antagonist protocol primed
with either daily estradiol for 5 days prior to the unset of menses,
or 12–14 days of oral contraceptive pills. Moreover, will long term
pretreatment with androgens, or short-term pretreatment with
growth hormone before and during stimulation have an effect
on the number of growing follicles and oocytes? This question
needs to be explored in future RCT’s. Another pending question
is whether DUOstim reduces time to live birth for groups 3 and 4.
An RCT comparing DUOStim to a long GnRHa down-regulation
protocol or a “primed” GnRH antagonist protocol is necessary to
answer this question. Here again, cumulative live birth (CLBR),
i.e., the live births obtained after one embryo transfer and the
subsequent frozen cycles within a 2–3-years period will be the
primary endpoint whereas the POSEIDON marker of success in
ART, namely, the number of mature oocytes needed to obtain at
least one euploid blastocyst as per the ART calculator estimation
will be the secondary endpoint (3).
CONCLUSIONS
The POSEIDON stratification has been well-accepted by
reproductive endocrinologists and infertility specialists
worldwide, however, this novel classification system needs
to be prospectively investigated. It is our hope that during
the following years POSEIDON and the ART calculator
will be an integral part of daily clinical practice used for
decision-making and counseling with the aims of providing
the most optimal treatment of the patient and reducing time to
live birth.
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